Among U.S. residents aged 12 and older who reported substance use in 2021-2023, past-year ketamine use was more common among those receiving substance use disorder treatment (1.39%) than among those not in treatment (0.22%). Treatment was associated with higher odds of ketamine use across multiple substance types, including alcohol, marijuana, inhalant, methamphetamine, pain reliever, and opioid use disorders. The findings suggest that past-year treatment may be a marker of elevated ketamine exposure, highlighting the need for clinical screening and patient education about unsupervised ketamine risks.
Using electronic health records, this cohort study examined associations between psychedelic use and adverse outcomes in people with substance use disorders. The analysis found that psychedelic use was linked to a higher risk of certain adverse events, including emergency department visits and hospitalizations, compared to no psychedelic use. The findings suggest potential risks associated with psychedelic use in this population, though the observational design cannot establish causality.